What's on

  • January 25, 2017

    A treatment increases survival by 50% in mice with Niemann-Pick type C, a rare disease that affects brain and liver

    Researchers from the IIBB-CSIC and the IDIBAPS publish an article in the journal Redox Biology in which they propose an alternative treatment for Niemann-Pick disease type C, a rare lysosomal pathology that causes neurodegeneration and impaired liver function. With a compound that crosses the blood-brain barrier, it is possible to increase the survival of the mice by 50% and to improve the neurological and motor problems related to the disease. Dr. José C. Fernández-Checa, head of the IDIBAPS team on Mitochondrial regulation of cell death and steatohepatitis, and Dr. Carmen García-Ruiz, from the same team, are the coordinators of the study, which has been carried out in collaboration with researchers from France and Chile. The first author of the study is Sandra Torres, predoctoral researcher in Dr. Fernández-Checa’s lab.

    Read the rest of this entry

  • January 18, 2017

    A diagnostic test for lung cancer detects genetic alterations which may remain hidden when conventional techniques are used

    A study led by researchers from Hospital Clínic-IDIBAPS, in collaboration with Dexeus University Hospital, shows the effectiveness of a new genetic test for molecular diagnosis in lung cancer. This is the first time that a test for this type of tumor is implemented in clinical practice. It consists of analyzing three genes with an innovative genomic technology that allows detecting multiple alterations which may not be identified when conventional diagnostic techniques are used. If these genetic alterations are detected, the patient can be treated with an oral drug that has minimal toxicity and a very high clinical benefit. The study has been coordinated by Dr. Noemí Reguart, an oncologist at the Hospital Clínic-IDIBAPS, and Dr. Aleix Prat, head of the Clinical Oncology Department and of the IDIBAPS research team on Translational Genomics and directed therapies in solid tumors.

    Read the rest of this entry

  • January 17, 2017

    Researchers discover a protein that protects against fatty liver, the most common hepatic disease in Western countries

    A team co-headed by scientists at the Institute for Research in Biomedicine (IRB Barcelona) and the IDIBAPS Biomedical Research Institute (part of the Hospital Clínic de Barcelona) has revealed the capacity of the CPEB4 protein to prevent fatty liver disease. This condition generally leads to chronic inflammation (non-alcoholic steatohepatitis), which can trigger fibrosis, cirrhosis and ultimately liver cancer. This study on the basic biology of the liver paves the way to examine therapeutic strategies to fight and prevent fatty liver disease. The results have appeared in Nature Cell Biology this week.

    Read the rest of this entry

  • January 16, 2017

    Hospital Clinic-IDIBAPS leads a European project to fight against cirrhosis within the Horizon 2020 program

    Hospital Clínic-IDIBAPS is leading a European project to evaluate the efficacy of treatment with the combination of rifaximin, an antibiotic that modulates the intestinal microbiome, and statins in patients with advanced cirrhosis. The project, called LIVERHOPE, will also focuse on the search for biomarkers of the disease. LIVERHOPE is coordinated by Dr. Pere Ginès, head of the Hepatology Department of the Hospital Clínic and of the team of Mechanisms of liver diseases and complications of cirrhosis of IDIBAPS, and a total of 16 institutions are participating among clinical centers, universities and European companies. This project is part of the Horizon 2020 European research and innovation framework program and it is endowed with a budget of 6 million euros.

    Read the rest of this entry

  • January 10, 2017

    Transplant Biomedical receives an economical injection to develop an organ preservation device

    Transplant Biomedical, one of the two spin-offs arising from IDIBAPS, will receive a maximum of 2.5 million euros to carry out the clinical phase of a medical device intended to improve the preservation and transport of kidneys and livers for transplantation. This economic injection is the result of an agreement with Caixa Capital Risc and Kereon Partners, the company founded, among others, by Carmen Peralta, coordinator of the group Strategies for the protection of hepatic injury induced by ischemia-reperfusion.

    Read the rest of this entry

Events

  • Tuesday, 09/26/2017 · Neuroscience Seminar

    Sergio Amaro // Elena Hernández Martínez

    Blood brain barrier disruption in acute ischemic stroke: assessment with perfusion neuroimaging and clinical relevance // Multimodal assessment of visual pathway: an opportunity to understand and monitor MS?
    Day:
    09/26/2017
    Place:
    Esteve Auditorium IDIBAPS CEK Building Rosselló 149-153
    Schedule:
    15:00
  • Wednesday, 09/27/2017 · IDIBAPS Core Facility Seminar

    Guillermo Horga

    Assistant Professor of Clinical Psychiatry University of Columbia

    Computational approaches to understand the neural mechanisms of psychosis. Evidence from fMRI, PET and behavioural studies
    Day:
    09/27/2017
    Place:
     Esteve Auditorium IDIBAPS CEK Building Rosselló 149-153
    Schedule:
    15:00
  • Wednesday, 10/04/2017 · Liver seminars

    Rajiv Jalan

    professor of hepatology at Unversitiy College London

    Acute on chronic liver failure
    Day:
    10/04/2017
    Place:
    IiSGM Auditorium  c/ O’Donnell 48, Madrid. Live streaming to IDIBAPS - Esteve Auditorium CEK Building Rosselló 149-153
    Schedule:
    16:00

More events